It is very uncertain whether linezolid changes treatment failure compared with no linezolid (very low certainty).
It is very uncertain whether linezolid changes treatment interrupted compared with no linezolid (very low certainty).
It is very uncertain whether linezolid changes treatment completed compared with no linezolid (very low certainty).
It is very uncertain whether linezolid changes antituberculous treatment discontinuationj compared with no linezolid (very low certainty).
It is very uncertain whether specific antipsychotic changes acceptability of the treatment: leaving the study early compared with other drugs (very low certainty).
It is very uncertain whether cognitive‐behavioural coping skills training (CBCST) changes number of participants achieving 3 or more weeks of consecutive… compared with twelve‐step facilitation (TSF) programme to reduce alcohol consumption (very low certainty).
Brief motivational interviewing (BMI) showed no clear difference in retention ‐ end of treatment compared with assessment‐only to reduce alcohol consumption (moderate certainty).
Motivational interviewing intensive (MII) may leads to higher retention ‐ end of treatment compared with motivational interviewing (MI) to reduce alcohol consumption (low certainty).
It is very uncertain whether cognitive‐behavioural coping skills training (CBCST) changes retention ‐ end of treatment compared with twelve‐step facilitation (TSF) programme to reduce alcohol consumption (very low certainty).
It is very uncertain whether tricyclics changes number not achieving 14 consecutive dry nights at the end of… compared with another drug (very low certainty).
FLUPHENAZINE showed no clear difference in response to treatment compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (moderate certainty).
FLUPHENAZINE showed no clear difference in acceptability of treatment‐leaving the study early due to any reason compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (moderate certainty).
HALOPERIDOL showed no clear difference in clinical response to treatment compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (low certainty).
Comparison 1: PERPHENAZINE showed no clear difference in response to treatment compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (moderate certainty).
It is very uncertain whether comparison 1: PERPHENAZINE changes acceptability of treatment ‐ leaving the study early due to any reason compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (very low certainty).
Trifluoperazine showed no clear difference in response to treatment ‐ medium term compared with low‐potency antipsychotic drugs (low certainty).
Trifluoperazine showed no clear difference in leaving the study early: 1. Acceptability of treatment ‐ leaving… compared with low‐potency antipsychotic drugs (low certainty).
Flunarizine probably leads to higher treatment withdrawal Number of withdrawals compared with placebo (moderate certainty).